Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1993-03-02
1999-11-30
Sidberry, Hazel F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241841, 530350, 5303881, 5303882, 435 691, 435 693, A61K 39102, A61K 3902, C07K 14285, C07K 16102
Patent
active
059938269
ABSTRACT:
The present disclosure relates to Moraxella catarrhalis outer membrane vesicle (OMV) compositions, to selected antigenic proteins from the outer membranes of M. catarrhalis which have a variety of useful properties, and to monoclonal antibodies against these proteins. Particular "Outer Membrane Proteins" (OMPs) of the invention are characterized as having molecular weights of about 30 kD, 80 kD (also termed CopB protein) and between about 200 and 700 kD (HMWP antigen). Passive immunization with monoclonal antibodies directed against these proteins confers protection against homologous and heterologous Moraxella catarrhalis strains in animal models, and active immunization with outer membrane vesicles also enhances pulmonary clearance of distinct M. catarrhalis strains. This demonstrates both the utility of antibodies in conferring passive immunity and the usefulness of OMPs, or variants thereof, in the preparation of vaccines. Also disclosed are DNA segments encoding these OMPs, methods for preparing the antigens, or variants, through the application of recombinant DNA techniques, as well as diagnostic methods and related embodiments.
REFERENCES:
patent: 4271147 (1981-06-01), Helting et al.
Bartos et al The Journal of Infect Dis 158: 761-765 1988.
Murphy The American Journ of Medicine 88: 41S-45S.
Goldblatt et al The Joun of Infect Dis. 162: 1128-1135, 1990.
Helminen et al. Infect & Immunity 61: 2003-2010 1993.
McGehee Am Journal of Respir. Cell Mol. Biol. 1: 201-216, 1989.
Doyle et al Peditr Infect Dis J. 8: 545-547 1989.
(Paul Siskind Fundamental Immunology Chapter 20 pp. 537-558.
Jonsson et al, Eur. J. of Clinical Microb & Infect Diseases, 1993 12: 289-293.
Consensus, Paediatr. Infect. Dis. J., 8(1):S94-S97, 1989.
Murphy & Loeb, "Isolation of the Outer Membrane of Branhamella catarrhalis," Microbial. Pathogenesis, 6:159-174, 1989.
Murphy, T.F., "The Surfae of Branhamella catarrhalis: A Systemic Approach to the Surface Antigens of an Emerging Pathogen," Paediatr. Infect. Dis. J., 8(1):S75-S77, 1989.
Murphy & Bartos, "Surface-Exposed and Antigenically Conserved Determinants of Outer Membrane Proteins of Branhamella catarrhalis," Infect. Immun., 57(1):2938-2941, 1989.
Eliasson, I., "A Protein Antigen Characteristic of Branhamella catarrhalis," Acta Path. Microbiol. Scand. Sect. B., 88:281-286, 1980.
Dialog Search Report.
Beaulieu & Roy, "Construction of a Species-Specific DNA Probe for Branhamella catarrhalis," 89th Annual Meeting of the American Society for Microbiology, New Orleans, LA, USA, May 14-18, 1989. Abstr. Annu. Meet. Am. Soc. Microbiol., 89(0), 1989, p. 124, Abstract #D-249.
Bhushan & Murphy, "Molecular Characterization of Outer Membrane Protein E. of Branhamella catarrhalis: A Potential Vaccine Candidate," 91st General Meeting of the American Society for Microbiology 1991, Dallas, Texas, USA, May 5-9, 1991, Abstr. Gen. Meet. Am. Soc. Microbiol., 91(0), 1991, p. 57, Abstact #B-191.
Black & Wilson, "Immunoglobulin G (IgG) Serological Response to Branhamella catarrhalis in Patients with Acute Bronchopulmonary Infections," J. Clin. Pathol., 41:329-333, 1988.
Chapman et al., "Development of Bactericidal Antibody During Branhamella catarrhalis Infection," J. of Infect. Dis., 151(5):878-882, 1985.
Helminen et al., "Molecular Cloning of a Gene Encoding a Surface-Exposed Outer Membrane Protein of Moraxella Catarrhalis," Abstract of the 1991 ICAA; 31 (O), p. 145, Abstract No. 278.
International Search Report, mailed Nov. 27, 1992.
Hanson, M.S. et al., "Expression of the Heat-Modifiable Major Outer Membrane Protein of Haemophilus influenzae Type b is Unrelated to Virulence," Infection and Immunity, 57(6):1639-1646, 1989.
Klingman, K.L. and Murphy, T.F., "Identification and Purification of the Lipooligosaccharide-Associated High Molecular Weight Outer Membrane Protein (HMW-OMP) of Branhamella catarrhalis," Abstract of the 92nd General Meeting of the American Society for Microbiology, p. 90, B-388, 1992.
Shenep, J.L., et al., "Further Studies of the Role of Noncapsular Antibody in Protection Against Experimental Haemophilus influenzae Type b Bacteremia," Infection and Immunity, 42(1): 257-263, 1983.
Srikumar, R., et al., "Monoclonal Antibodies Specific to Porin of Haemophilus influenzae Type b: Localization of Their Cognate Epitopes and Tests of Their Biological Activities," Molecular Microbiology, 6(5):665-676, 1992.
Yogev, R. and Hansen, E.J., "Disassociation of Virulence and Protection from Infection by Mutant Analysis in Haemophilus influenzae Type b," Infection and Immunity, 55(8):1944-1947, 1987.
Barinaga, "New Technique Offers a Window on Bacteria's Secret Weapons," Science, 259:595, 1993.
Chi et al., "Antibody Response to P-Protien in Pateints with Branhamella catarrhalis Infections," The American Journal of Medicine, 88 (suppl.5A):5A-25S, 1990.
Eliasson, "A Protein Antigen Characteristic of Branhamella Catarrhalis," Acta Path. Microbiol. Scand. Sect. B, 88:281-286, 1980.
Hanson et al., "Expression of the Heat-Modifiable Major Outer Membrane Protein of Haemophilus influenzae Type b Is Unrelated to Virulence," Infection and Immunity, 57(6):1639-1646, 1989.
Mahan et al., "Selection of Bacterial Virulence Genes That Are Specifically Induced in Host Tissues," Science,259:686-388, 1993.
Rustici et al., "Molecular Mapping and Detoxification of the Lipid A Binding Site by Synthetic Peptides," Science, 259:361-364, 1993.
Zollinger et al., "Safety and Immunogenicity of a Neisseria meningitidis Type 2 Protein Vaccine in Animals and Humans," The Journal of Infectious Diseases, 137(6):728-739, 1978.
Zollinger et al., "Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in Man," The Journal of Clinical Investigation, 63:836-848, 1979.
Hansen Eric J.
Helminen Meria E.
Maciver Isobel
Board of Regents The University of Texas
Sidberry Hazel F.
LandOfFree
Methods and compositions relating to useful antigens of moraxell does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to useful antigens of moraxell, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to useful antigens of moraxell will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1668203